FENTANYL HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H28N2O.ClH
Molecular Weight	372.931
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCC(=O)N(C1CCN(CCC2=CC=CC=C2)CC1)C3=CC=CC=C3

InChI

InChIKey=LHCBOXPPRUIAQT-UHFFFAOYSA-N

InChI=1S/C22H28N2O.ClH/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19;/h3-12,21H,2,13-18H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H28N2O
Molecular Weight	336.4705
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9618424
Curator's Comment: Description was created based on several sources, including https://www.addictioncenter.com/painkillers/fentanyl/ | https://www.ncbi.nlm.nih.gov/pubmed/24635521

Fentanyl is a potent agonist of mu opioid receptor. It is used to relieve severe pain, such as after surgery or during cancer treatment, and breakthrough pain (flare-ups of intense pain despite round-the-clock narcotic treatment). Fentanyl is an extremely powerful analgesic, 50–100-times more potent than morphine. Fentanyl harbors massive risk for addiction and abuse regardless of its prescription form. Fentanyl abuse is especially dangerous to those without a tolerance to opioids. The substance’s already elevated risk of overdose is multiplied when someone without a tolerance abuses it.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mu opioid receptor 221 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9618424 \| https://www.ncbi.nlm.nih.gov/pubmed/6304563	Agonist 2678		0.15 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016619s034lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/19813s039lbl.pdf	Primary		Approved 8429	DURAGESIC-100 Approved Use Fentanyl transdermal system is a transdermal formulation of fentanyl indicated for the management of persistent, moderate to severe chronic pain in opioid-tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is required for an extended period of time, and the patient cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. Patients considered opioid-tolerant are those who are taking at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid for a week or longer. Fentanyl transdermal system contains fentanyl, a full opioid agonist. Fentanyl transdermal system is indicated for the management of persistent, moderate to severe chronic pain in opioid‑tolerant patients 2 years of age and older when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. (1) Fentanyl transdermal system is NOT intended for use as an as-needed analgesic. (1) Launch Date 1990

C_max

Value	Dose	Analyte	Population
0.91 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.61 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.81 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1.76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.18 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5.76 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
4.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	100 μg single, intravenous dose: 100 μg route of administration: Intravenous experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, oral transmucosal dose: 400 μg route of administration: Oral transmucosal experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23497761/	400 μg single, sublingual dose: 400 μg route of administration: Sublingual experiment type: SINGLE co-administered:	FENTANYL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 mg single, transdermal (total) Overdose Dose: 6 mg Route: transdermal Route: single Dose: 6 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22561319 Page: p.463	healthy, 15 n = 1 Health Status: healthy Age Group: 15 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/22561319 Page: p.463	Disc. AE: Apnea, Respiratory depression... AEs leading to discontinuation/dose reduction: Apnea Respiratory depression Bradypnea Tachycardia Diaphoresis Sources: https://pubmed.ncbi.nlm.nih.gov/22561319 Page: p.463
150 ug 1 times / hour multiple, transdermal Overdose Dose: 150 ug, 1 times / hour Route: transdermal Route: multiple Dose: 150 ug, 1 times / hour Sources: https://pubmed.ncbi.nlm.nih.gov/9695458	unknown, 31 n = 1 Health Status: unknown Age Group: 31 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9695458	Disc. AE: Respiratory arrest... AEs leading to discontinuation/dose reduction: Respiratory arrest (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/9695458
225 ug 1 times / hour multiple, transdermal Overdose Dose: 225 ug, 1 times / hour Route: transdermal Route: multiple Dose: 225 ug, 1 times / hour Sources: https://pubmed.ncbi.nlm.nih.gov/25736329 Page: p.51	unhealthy, 32 n = 1 Health Status: unhealthy Condition: Knee pain Age Group: 32 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25736329 Page: p.51	Disc. AE: Syncope, Acute coronary syndrome... AEs leading to discontinuation/dose reduction: Syncope Acute coronary syndrome Sources: https://pubmed.ncbi.nlm.nih.gov/25736329 Page: p.51
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 14	healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 14	Other AEs: Hypoxia, Nausea... Other AEs: Hypoxia (50%) Nausea (75%) Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 14
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 15	healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 15	Other AEs: Somnolence... Other AEs: Somnolence (87.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 15
800 ug single, sublingual Higher than recommended Dose: 800 ug Route: sublingual Route: single Dose: 800 ug Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 16	healthy, 33.4 n = 8 Health Status: healthy Age Group: 33.4 Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 16	Other AEs: Vomiting... Other AEs: Vomiting (50%) Sources: https://pubmed.ncbi.nlm.nih.gov/28942715 Page: p.13, 16
1600 ug 1 times / 15 min multiple, sublingual (max) Highest studied dose Dose: 1600 ug, 1 times / 15 min Route: sublingual Route: multiple Dose: 1600 ug, 1 times / 15 min Sources: https://pubmed.ncbi.nlm.nih.gov/10068176 Page: p.309	unhealthy, 53±12 n = 65 Health Status: unhealthy Condition: Pain Age Group: 53±12 Sex: M+F Population Size: 65 Sources: https://pubmed.ncbi.nlm.nih.gov/10068176 Page: p.309	Disc. AE: Somnolence, Dizziness... AEs leading to discontinuation/dose reduction: Somnolence (3%) Dizziness (3%) Hallucinations (1.5%) Dry mouth (1.5%) Headache (1.5%) Nausea (1.5%) Vomiting (1.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/10068176 Page: p.309
5 mg single, intravenous Accidental dose Dose: 5 mg Route: intravenous Route: single Dose: 5 mg Sources: https://pubmed.ncbi.nlm.nih.gov/9060031 Page: p.199	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Pain Age Group: 62 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9060031 Page: p.199	Disc. AE: Confusion, Restlessness... AEs leading to discontinuation/dose reduction: Confusion (acute) Restlessness (mild) Visual hallucinations Sweating Miosis Sources: https://pubmed.ncbi.nlm.nih.gov/9060031 Page: p.199
200 ug 6 times / day multiple, sublingual Recommended Dose: 200 ug, 6 times / day Route: sublingual Route: multiple Dose: 200 ug, 6 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf Page: p.1	Disc. AE: Respiratory depression, Opioid abuse... AEs leading to discontinuation/dose reduction: Respiratory depression (grade 4) Opioid abuse Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020747s030lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	substrate 1037	substrate 1217 inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2B6 810 CYP1A2 1524 CYP2A6 707 CYP2C8/9 44 CYP2E1 882 P-gp 1461 OCT1 512 OATP1B1 788 OATP1B3 706 OATP2B1 123	CYP1A1 349 CYP1A2 1054 CYP2C8 693 CYP2C18 138 CYP2C19 991 CYP2E1 667 CYP3A5 395 CYP3A7 110 P-gp 1537 OATP1A2 62 OATP1B1 406 OCT1 327

Drug as perpetrator

Target	Modality	Activity	Metabolite
CYP2C8/9 44	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	likely
CYP2D6 1891	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	likely
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	no
OATP1B1 803	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	no
CYP1A2 1692	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	weak
CYP2A6 739	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	weak
OATP1B3 715	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	weak
OATP2B1 126	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/	weak
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/31597043/	yes [IC50 117.7 uM]	NORFENTANYL 3
OCT1 543	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/18788725/, https://pubmed.ncbi.nlm.nih.gov/31597043/, http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50008984&submit=repeat&energyterm=&column=EC50&startPg=50&Increment=50	yes [IC50 46.2 uM]
P-gp 1650	inhibitor 3277 Sources: https://go.drugbank.com/drugs/DB00813, https://pubmed.ncbi.nlm.nih.gov/11964599/, https://www.ema.europa.eu/en/documents/assessment-report/instanyl-epar-public-assessment-report_en.pdf#page=10 Page: (EMA PAR) 10	yes [IC50 6.5 uM]
CYP2B6 1001	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17101742/	yes
CYP3A4 1925	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	likely
CYP2C18 138	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	likely
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	likely
CYP3A4 1737	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20747_Actiq_phrmr.pdf#page=17, https://pubmed.ncbi.nlm.nih.gov/9264313/, https://www.pmda.go.jp/drugs/2001/P200100034/80015500_21300AMY00455_263_1.pdf#page=17, https://pubmed.ncbi.nlm.nih.gov/10485779/ Page: (Pharm) 17, 28, (PMDA) 17	major		yes (co-administration study) Comment: Rate: 61 pmol/min/mg protein; Activity (Fentanyl): 1.03 nmol/min/nmol CYP (Biochem Pharmacol, 53, 1613 (1997)); Coadministartion of Ritonavir (strong CYP3A inhibitor, PO) increased Fentanyl (IV) AUCinf by 2.74-fold. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20747_Actiq_phrmr.pdf#page=17, https://pubmed.ncbi.nlm.nih.gov/9264313/, https://www.pmda.go.jp/drugs/2001/P200100034/80015500_21300AMY00455_263_1.pdf#page=17, https://pubmed.ncbi.nlm.nih.gov/10485779/ Page: (Pharm) 17, 28, (PMDA) 17
CYP1A1 349	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	minor
CYP2C19 991	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	minor
CYP2C8 693	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	minor
CYP2D6 1217	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	minor
OATP1B1 406	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/23480028/	no
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31597043/	no
P-gp 1537	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/11964599/	no
CYP2C9 1037	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	yes
CYP3A5 395	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/9264313/	yes
CYP3A7 110	substrate 3367 Sources: https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.02d&code=C494&ns=ncit&type=relationship&key=n1099999666&b=1&n=0&vse=null	yes
OATP1A2 62	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31746415/	yes
OCT1 327	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/31597043/	yes	NORFENTANYL 3

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://pubmed.ncbi.nlm.nih.gov/32321735/, , https://pubmed.ncbi.nlm.nih.gov/15911273/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:119915	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:119915
ZINC	ZINC000002522669	http://zinc15.docking.org/substances/ZINC000002522669
eMolecules	901881	https://www.emolecules.com/cgi-bin/more?vid=901881

PubMed

Title	Date	PubMed
Spasm and operative cholangiography.	1975 Jan	1119938
Horner's syndrome due to epidural analgesia.	1998 Dec	10051945
Seizure and electroencephalographic changes in the newborn period induced by opiates and corrected by naloxone infusion.	1999 Mar	10642972
Continuous paravertebral extrapleural infusion for post-thoracotomy pain management.	1999 Oct	10520911
Potentiation of narcosis after intravenous lidocaine in a patient given spinal opioids.	1999 Sep	10475320
Patient-controlled intranasal analgesia: effective alternative to intravenous PCA for postoperative pain relief.	2000 Apr	10764171
Comparison of intravenous and oral ketoprofen for postoperative pain after adenoidectomy in children.	2000 Aug	10992828
Acute adverse reaction to fentanyl in a 55 year old man.	2000 Aug	10960295
Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine.	2000 Feb	10691234
Low-dose clonidine and neostigmine prolong the duration of intrathecal bupivacaine-fentanyl for labor analgesia.	2000 Feb	10691221
A direct search procedure to optimize combinations of epidural bupivacaine, fentanyl, and clonidine for postoperative analgesia.	2000 Feb	10691217
Minidose bupivacaine-fentanyl spinal anesthesia for surgical repair of hip fracture in the aged.	2000 Jan	10638892
Anaesthetic agents inhibit gastrin-stimulated but not basal histamine release from rat stomach ECL cells.	2000 Jun	10864877
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.	2000 Oct	11027906
A comparison of minidose lidocaine-fentanyl and conventional-dose lidocaine spinal anesthesia.	2000 Oct	11004039
Abuse of topical analgesic.	2001 Apr	11282708
Patient-controlled spinal analgesia for labour and caesarean delivery.	2001 Feb	11261914
[Anesthesia in a case of Bardet-Biedl syndrome].	2001 Feb	11257962
[Anesthetic management for the correction of pectus excavatum using pectus bar under video-assistance].	2001 Feb	11244773
A randomized prospective comparative study of general versus epidural anesthesia for transcervical hysteroscopic endometrial resection.	2001 Feb	11228472
Nociceptin/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain.	2001 Feb	11181645
Effect of midazolam pretreatment on induction dose requirements of propofol in combination with fentanyl in younger and older adults.	2001 Feb	11167469
Intestinal inflammation enhances the inhibitory effects of opioids on intestinal permeability in mice.	2001 Feb	11160621
Levobupivacaine for epidural analgesia in labor: the sparing effect of epidural fentanyl.	2001 Feb	11159242
Transdermal fentanyl for chronic pain in AIDS: a pilot study.	2001 Jan	11223316
[Low concentration/high volume is more effective than high concentration/low volume for postoperative continuous epidural analgesia with the combination of bupivacaine and fentanyl].	2001 Jan	11211743
[The effects of intravenous nicardipine on jugular venous oxygen saturation].	2001 Jan	11211742
Digitally assisted acromioplasty: the effect of interscalene block on this new surgical technique.	2001 Jan	11154366
The influence of halothane, isoflurane and sevoflurane on rocuronium infusion in children.	2001 Jan	11152037
Opiates, intracranial pressure, and autoregulation.	2001 Jan	11135743
Buprenorphine substitution ameliorates spontaneous withdrawal in fentanyl-dependent rat pups.	2001 Jan	11134491
Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes.	2001 Jan 1	11137281
Distressing upper extremity phantom limb sensation during intravenous regional anesthesia.	2001 Jan-Feb	11172516
Opiate self-administration as a measure of chronic nociceptive pain in arthritic rats.	2001 Mar	11240076
Neural circuits regulating pulsatile luteinizing hormone release in the female guinea-pig: opioid, adrenergic and serotonergic interactions.	2001 Mar	11207938

Patents

Sample Use Guides

In Vivo Use Guide

Dosage should be individualized. Some of the factors to be considered in determining the dose are age, body weight, physical status, underlying pathological condition, use of other drugs, type of anesthesia to be used and the surgical procedure involved. Dosage should be reduced in elderly or debilitated patients (see PRECAUTIONS). Vital signs should be monitored routinely. I. Premedication — Premedication (to be appropriately modified in the elderly, debilitated and those who have received other depressant drugs) — 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly 30 to 60 minutes prior to surgery. II. Adjunct to General Anesthesia — See Dosage Range Chart III. Adjunct to Regional Anesthesia - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly or slowly intravenously, over one to two minutes, when additional analgesia is required. IV. Postoperatively (recovery room) - 50 to 100 mcg (0.05 to 0.1 mg) (1 to 2 mL) may be administered intramuscularly for the control of pain, tachypnea and emergence delirium. The dose may be repeated in one to two hours as needed

Route of Administration: Other

In Vitro Use Guide

0.5 - 5 ng/ml fentanyl inhibited viability of SW1990 cells in vitro.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:39:16 GMT 2023` Edited by `admin` on `Fri Dec 15 15:39:16 GMT 2023`
Record UNII	59H156XY46
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FENTANYL HYDROCHLORIDE

Common Name

English

FENTANYL HYDROCHLORIDE [EMA EPAR]

Common Name

English

FENTANYL HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

Fentanyl hydrochloride [WHO-DD]

Common Name

English

FENTANYL HCL

Common Name

English

FENTANYL HYDROCHLORIDE [MART.]

Common Name

English

IONSYS

Brand Name

English

PROPANAMIDE, N-PHENYL-N-(1-(2-PHENYLETHYL)-4-PIPERIDINYL)-, MONOHYDROCHLORIDE

Common Name

English

FENTANYL HYDROCHLORIDE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C67413